文献速递临床试验与 GCP真实世界研究与卫生经济

甲氨蝶呤口服与皮下注射治疗类风湿关节炎(MOOSE):多中心随机试验研究方案

Methotrexate oral or subcutaneous for rheumatoid arthritis (MOOSE): study protocol for a multi-centre randomised trial.
PubMed 文献 · Trials · 2025-11-12

MOOSE试验为开放标签、多中心、评估者盲法、两臂随机对照试验,纳入NHS医院风湿科门诊的成人类风湿关节炎患者,比较口服与皮下甲氨蝶呤作为一线改善病情抗风湿药的临床与成本效果,主要结局为24周缓解,随访52周,并嵌套可行性评估、经济学评价与定性研究。

要点

  • 口服甲氨蝶呤为类风湿关节炎一线改善病情抗风湿药,皮下注射通常用于胃肠道不耐受或疗效欠佳时。
  • MOOSE试验旨在比较皮下与口服甲氨蝶呤作为一线治疗的临床与成本效果,并评估两种给药途径的可接受性。
  • 试验为开放标签、多中心、评估者盲法、两臂随机对照设计,主要结局为24周缓解,随访52周。

核心结论

  • MOOSE研究将提供口服与皮下甲氨蝶呤给药途径的临床与成本效果证据,以回答皮下还是口服甲氨蝶呤作为类风湿关节炎一线治疗这一对患者和临床医生重要的问题。

研究设计与样本

  • MOOSE为开放标签、多中心、评估者盲法、两臂随机对照试验,嵌套内部可行性评估、经济学评价与定性研究。
  • 试验在NHS医院风湿科门诊开展,于患者初次就诊前后邀请潜在合格患者参与。
  • 同意参与的患者随机分配至口服或皮下甲氨蝶呤,随机化按试验中心、28关节疾病活动度评分和病程进行最小化。
  • 干预以开放标签处方,参与者和临床医生知晓治疗分配,结局评估者对治疗分配设盲。
  • 每名参与者参与试验52周,主要结局为24周时评估的缓解。

主要发现

  • 次要结局包括疾病活动度、生活质量、心理健康和就业。
  • 定性研究将通过半结构化访谈分析干预措施的可接受性。
  • 健康经济学研究将利用医疗服务利用数据、生活质量数据和成本估计来建模成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis is the commonest chronic inflammatory arthritis. Oral methotrexate is recommended as the first-line disease modifying drug for its management, and subcutaneous injections are typically prescribed if there is gastrointestinal intolerance or suboptimal efficacy. It is not known whether subcutaneous methotrexate is more effective and cost-effective compared to oral methotrexate when used as first-line treatment in people diagnosed with rheumatoid arthritis. The Methotrexate Oral Or SubcutanEous (MOOSE) trial aims to compare the clinical and cost-effectiveness of subcutaneous and oral methotrexate when used as first-line disease modifying anti-rheumatic drug in adults with rheumatoid arthritis and collect information about the acceptability of both routes of administration. METHODS: MOOSE is an open-label, multi-centre, assessor-blinded, two-arm randomised controlled trial, with an internal feasibility assessment, economic evaluation and qualitative study. It is a secondary care-based trial, involving NHS hospital rheumatology clinics. Potentially eligible patients will be approached to participate around the time of their initial clinic visit. Eligible patients who consent will be randomised to either oral or subcutaneous methotrexate. Randomisation will be minimised by trial centre, 28-joint disease activity score, and disease duration. Interventions will be prescribed open-label with participants and clinicians aware of treatment allocated. Outcome assessors will be blinded to treatment allocation. Each participant will be in the trial for 52 weeks. The primary outcome is remission assessed at 24 weeks. Secondary outcomes include disease activity, quality of life, mental health and employment. A qualitative study will involve semi-structured interviews to analyse the acceptability of interventions. The health economic study will use healthcare utilisation data, quality of life data, and cost-estimates to model cost-effectiveness. DISCUSSION: Whether to use subcutaneous or oral methotrexate first line for RA is an important question for patients and clinicians. MOOSE study will provide evidence on the clinical and cost-effectiveness of oral and subcutaneous routes of methotrexate administration to answer this important question. TRIAL REGISTRATION: Prospectively registered with the International Standard Randomised Controlled Trial Number (ISRCTN) 14,403,521. Registered on 03 August 2023 https://doi.org/10.1186/ISRCTN14403521 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. McClure S, Haydock R, Su Y, et al. Methotrexate oral or subcutaneous for rheumatoid arthritis (MOOSE): study protocol for a multi-centre randomised trial. Trials. 2025. PMID: 41225576. doi:10.1186/s13063-025-09020-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。